Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)

Pneumologie ◽

10.1055/s-0032-1302561 ◽

2012 ◽

Vol 66 (S 01) ◽

Author(s):

J von Pawel ◽

R Jotte ◽

DR Spigel ◽

MA Socinski ◽

MER O'Brien ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Download Full-text

Abstract CT071: LUNAR - A phase 3 trial of TTFields in combination with PD-1 inhibitors or docetaxel for second line treatment of non-small cell lung cancer (NSCLC)

10.1158/1538-7445.am2017-ct071 ◽

2017 ◽

Author(s):

Uri Weinberg ◽

Ori Farber ◽

Moshe Giladi ◽

Ze'ev Bomzon ◽

Eilon Kirson

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Download Full-text

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30104-8 ◽

2016 ◽

Vol 17 (8) ◽

pp. 1147-1157 ◽

Author(s):

Koichi Goto ◽

Yuichiro Ohe ◽

Taro Shibata ◽

Takashi Seto ◽

Toshiaki Takahashi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Combined Chemotherapy ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Download Full-text

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(10)70132-7 ◽

2010 ◽

Vol 11 (7) ◽

pp. 619-626 ◽

Author(s):

Roy S Herbst ◽

Yan Sun ◽

Wilfried EE Eberhardt ◽

Paul Germonpré ◽

Nagahiro Saijo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Download Full-text

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30461-7 ◽

2020 ◽

Vol 21 (9) ◽

pp. 1224-1233 ◽

Author(s):

Nathalie Baize ◽

Isabelle Monnet ◽

Laurent Greillier ◽

Margaux Geier ◽

Hervé Lena ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Download Full-text

OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.08.490 ◽

2019 ◽

Vol 14 (10) ◽

pp. S246 ◽

Author(s):

N. Baize ◽

I. Monnet ◽

L. Greillier ◽

M. Geier ◽

H. Lena ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Download Full-text

Faculty Opinions recommendation of Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718451079.793497341 ◽

2014 ◽

Author(s):

Laurie Carr

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Stage Iv ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Download Full-text

Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.02.009 ◽

2021 ◽

Author(s):

Fiona Blackhall ◽

Kevin Jao ◽

Laurent Greillier ◽

Byoung Chul Cho ◽

Konstantin Penkov ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Second Line Therapy ◽

Phase 3 ◽

Download Full-text

Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us

Value in Health ◽

10.1016/j.jval.2015.09.1174 ◽

2015 ◽

Vol 18 (7) ◽

pp. A457-A458 ◽

Author(s):

C Graham ◽

H Knox ◽

LM Hess ◽

M Jen ◽

G Cuyun Carter ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Download Full-text

Re‐Evaluating Progression in an Era of Progress: A Review of First‐ and Second‐Line Treatment Options in Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer

The Oncologist ◽

10.1634/theoncologist.2015-0396 ◽

2016 ◽

Vol 21 (6) ◽

pp. 755-761 ◽

Author(s):

Emily H. Castellanos ◽

Leora Horn

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Treatment Options ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Download Full-text

Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?

Current Oncology ◽

10.3747/co.23.2955 ◽

2016 ◽

Vol 23 (2) ◽

pp. 160 ◽

Author(s):

K.A. Ma ◽

G. Kasymjanova ◽

V. Cohen ◽

J. Agulnik

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Small Cell Lung

-

Download Full-text